Imafuku S, Okubo Y, Tada Y, Ohtsuki M, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial. J Dermatol 2024 Jan 24. doi: 10.1111/1346-8138.17074.
PMID: 38268101